secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K/A
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001193125-23-097964
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus finalizes employment terms for Interim CEO Anthony Bihl with $751K base salary
--------------------------------------------------------------------------------

- Base salary of $751,000 per year; target annual bonus of 100% of base salary.
- Equity awards: options for 198,000 shares and RSUs for 76,000 shares, both vesting fully on first anniversary.
- Change-in-control severance: 18 months base salary, 150% target bonus, 18 months COBRA, plus full equity acceleration.
- Restrictive covenants include perpetual confidentiality, non-disparagement, and 12-month non-compete (18 months after CIC).
- Agreement effective April 5, 2023; signed on April 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523097964/0001193125-23-097964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312523097964/d480678d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-097964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer